Role of immunotherapy for renal cell cancer in 2011

Saby George, Roberto Pili, Michael A. Carducci, Jenny Kim

Research output: Contribution to journalReview articlepeer-review


High-dose interleukin-2 (IL-2) and interferon were the most commonly administered therapies before the recent introduction of targeted agents, including vascular endothelial growth factor and mammalian target of rapamycin pathway inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. Lastly, improved understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of immunotherapy in the management of metastatic RCC.

Original languageEnglish (US)
Pages (from-to)1011-1018
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number9
StatePublished - Sep 1 2011


  • Immunotherapy
  • Interleukin
  • Renal cell cancer
  • Tumor immunity

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Role of immunotherapy for renal cell cancer in 2011'. Together they form a unique fingerprint.

Cite this